Literature DB >> 10611314

The N-terminal 209-aa domain of high molecular-weight 4.1R isoforms abrogates 4.1R targeting to the nucleus.

C M Luque1, M J Lallena, C M Pérez-Ferreiro, Y de Isidro, G De Cárcer, M A Alonso, I Correas.   

Abstract

An extensive repertoire of protein 4.1R isoforms is predominantly generated by alternative pre-mRNA splicing and differential usage of two translation initiation sites. The usage of the most upstream ATG (ATG-1) generates isoforms containing N-terminal extensions of up to 209 aa compared with those translated from the downstream ATG (ATG-2). To characterize nonerythroid 4.1R proteins translated from ATG-1 and analyze their intracellular localization, we cloned 4.1R cDNAs containing this translation initiation site. Six different clones were isolated from the nucleated human MOLT-4 T-cell line by reverse transcriptase-PCR techniques. Transient expression of the six ATG-1-translated 4.1R isoforms tagged with a c-Myc epitope revealed that all of them predominantly distributed to the plasma membrane and the endoplasmic reticulum. Staining of MOLT-4 cell plasma membranes but not nuclei was also observed by immunofluorescence microscopy by using an antibody specific to the N-terminal extension. Consistent with this, the antibody reacted with a major endogenous protein of approximately 145 kDa present in nonnuclear but absent from nuclear fractions prepared from MOLT-4 cells. Because these data suggested that ATG-1-translated 4.1R isoforms were predominantly excluded from the nucleus, we fused the 209-aa domain to nuclear 4.1R isoforms encoded from ATG-2 and observed that this domain inhibited their nuclear targeting. All these results indicate that the N-terminal domain of ATG-1-translated 4.1R isoforms plays a pivotal role in differential targeting of proteins 4.1R.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10611314      PMCID: PMC24749          DOI: 10.1073/pnas.96.26.14925

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Multiple protein 4.1 isoforms produced by alternative splicing in human erythroid cells.

Authors:  J G Conboy; J Chan; N Mohandas; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 3.  Structure, function, and molecular genetics of erythroid membrane skeletal protein 4.1 in normal and abnormal red blood cells.

Authors:  J G Conboy
Journal:  Semin Hematol       Date:  1993-01       Impact factor: 3.851

4.  Organization of the human protein 4.1 genomic locus: new insights into the tissue-specific alternative splicing of the pre-mRNA.

Authors:  F Baklouti; S C Huang; T J Vulliamy; J Delaunay; E J Benz
Journal:  Genomics       Date:  1997-02-01       Impact factor: 5.736

5.  Mechanisms of cytoskeletal regulation: modulation of aortic endothelial cell protein band 4.1 by the extracellular matrix.

Authors:  T L Leto; B M Pratt; J A Madri
Journal:  J Cell Physiol       Date:  1986-06       Impact factor: 6.384

6.  Identification of the functional site of erythrocyte protein 4.1 involved in spectrin-actin associations.

Authors:  I Correas; T L Leto; D W Speicher; V T Marchesi
Journal:  J Biol Chem       Date:  1986-03-05       Impact factor: 5.157

7.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.

Authors:  G I Evan; G K Lewis; G Ramsay; J M Bishop
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

8.  Transcription-dependent redistribution of nuclear protein 4.1 to SC35-enriched nuclear domains.

Authors:  M J Lallena; I Correas
Journal:  J Cell Sci       Date:  1997-01       Impact factor: 5.285

9.  Structural protein 4.1 in the nucleus of human cells: dynamic rearrangements during cell division.

Authors:  S W Krauss; C A Larabell; S Lockett; P Gascard; S Penman; N Mohandas; J A Chasis
Journal:  J Cell Biol       Date:  1997-04-21       Impact factor: 10.539

10.  Heterogeneity of mRNA and protein products arising from the protein 4.1 gene in erythroid and nonerythroid tissues.

Authors:  T K Tang; Z Qin; T Leto; V T Marchesi; E J Benz
Journal:  J Cell Biol       Date:  1990-03       Impact factor: 10.539

View more
  6 in total

Review 1.  The spectrin-ankyrin-4.1-adducin membrane skeleton: adapting eukaryotic cells to the demands of animal life.

Authors:  Anthony J Baines
Journal:  Protoplasma       Date:  2010-07-29       Impact factor: 3.356

2.  Protein 4.1R self-association: identification of the binding domain.

Authors:  Carmen M Pérez-Ferreiro; Eva Lospitao; Isabel Correas
Journal:  Biochem J       Date:  2006-12-15       Impact factor: 3.857

3.  Cytoskeleton protein 4.1R regulates B-cell fate by modulating the canonical NF-κB pathway.

Authors:  Taotao Liang; Yuying Guo; Mengjia Li; Cong Ding; Siyao Sang; Tingting Zhou; Qi Shao; Xin Liu; Jike Lu; Zhenyu Ji; Ting Wang; Qiaozhen Kang
Journal:  Immunology       Date:  2020-09-29       Impact factor: 7.397

4.  Cytoskeletal protein 4.1R negatively regulates T-cell activation by inhibiting the phosphorylation of LAT.

Authors:  Qiaozhen Kang; Yu Yu; Xinhong Pei; Richard Hughes; Susanne Heck; Xihui Zhang; Xinhua Guo; Gregory Halverson; Narla Mohandas; Xiuli An
Journal:  Blood       Date:  2009-02-03       Impact factor: 22.113

5.  NMR characterisation of the minimal interacting regions of centrosomal proteins 4.1R and NuMA1: effect of phosphorylation.

Authors:  Miguel A Treviño; Mar Rodríguez-Rodríguez; Isabel Correas; Miguel Marcilla; Juan P Albar; Manuel Rico; M Angeles Jiménez; Marta Bruix
Journal:  BMC Biochem       Date:  2010-01-28       Impact factor: 4.059

6.  An internal ribosome entry site element directs the synthesis of the 80 kDa isoforms of protein 4.1R.

Authors:  Eva Lospitao; Carmen M Pérez-Ferreiro; Altea Gosálbez; Miguel A Alonso; Isabel Correas
Journal:  BMC Biol       Date:  2008-12-04       Impact factor: 7.431

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.